Poolbeg Pharma (LON:POLB) Shares Down 6.4% – Should You Sell?

Poolbeg Pharma PLC (LON:POLB) was down 6.4% during mid-day trading on Monday . The stock traded as low as GBX 7.60 and last traded at GBX 8.05. Approximately 3,195,051 shares changed hands during trading, an increase of 96% from the average daily volume of 1,628,823 shares. The stock had previously closed at GBX 8.60.

Wall Street Analysts Forecast Growth

Separately, Shore Capital Group reissued a “house stock” rating on shares of Poolbeg Pharma in a research note on Tuesday, May 26th.

Poolbeg Pharma Trading Down 1.2%

The stock’s fifty day moving average price is GBX 5.07 and its 200 day moving average price is GBX 4.53. The stock has a market cap of £53.66 million, a P/E ratio of -8.10 and a beta of 1.82.

Poolbeg Pharma (LON:POLB) last issued its quarterly earnings results on Tuesday, April 28th. The company reported GBX (0.94) earnings per share (EPS) for the quarter. As a group, sell-side analysts forecast that Poolbeg Pharma PLC will post -0.68 earnings per share for the current year.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.